ACCL1333

A study designed to evaluate the safety and efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in children with newly diagnosed Acute Lympho.

Type: Treatment

Principal Investigator: Richard Drachtman, MD

Trial is open for enrollment

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

ACURATE

Evaluation of the safety and efficacy of the Acurate valve for transcatheter aortic valve replacement (TAVR)

Type: Device trial

Principal Investigator: Mark Russo, MD

Trial is open for enrollment

For inquiries, call (732) 235-9215

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

AEGIS II

A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

Type: Treatment

Trial is open for enrollment

• RWJ University Hospital Somerset

ALIGN-AR

To evaluate the safety and effectiveness/performance of the Transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation.

Type: Device trial

Principal Investigator: Mark Russo, MD

Trial is open for enrollment

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

ALIGN-AS

To evaluate the safety and effectiveness/performance of the Transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic stenosis.

Type: Device trial

Principal Investigator: Mark Russo, MD

Trial is open for enrollment

For inquiries, call (732) 235-9215

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

AMULET

A study designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder.

Type: Device trial

Trial is not open for enrollment

• Saint Barnabas Medical Center

ARRAY 797-301

A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.

Type: Drug trial

Principal Investigator: Saurabh Kapoor, MD

Trial is open for enrollment

• Newark Beth Israel Medical Center

ASAP-TOO

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

Type: Device trial

Principal Investigator: David Dobesh, MD

Trial is open for enrollment

• Saint Barnabas Medical Center

CIRT

A randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.

Type: Drug trial

Principal Investigator: John B. Kostis, MD

Trial is open for enrollment

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

CLASP II TR

A study designed to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation.

Principal Investigator: Mark Russo, MD

Type: Device

This trial is open for enrollment

• Robert Wood Johnson University Hospital
• RWJ University Hospital Somerset

CLASP IID & IIF

Evaluation of the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

Type: Device trial

Principal Investigator: Mark Russo, MD

Trial is open for enrollment

• Rutgers Robert Wood Johnson Medical School
• Robert Wood Johnson University Hospital

COMPASSION XT PAS

Evaluation of the longer-term safety and effectiveness of the SAPIEN XT transcatheter heart valve (THV) in the pulmonic position for the intended patient population (especially pediatric) when used as indicated with all valve sizes.

Type: Device trial

Principal Investigator: Marc Cohen, MD and Rajiv Verma, MD

Trial is not open for enrollment

• Newark Beth Israel Medical Center